Alkermes' alixorexton has become the first drug in the orexin 2 receptor agonist class to show efficacy in phase 2 trials involving patients with both main subtypes of sleep disorder narcolepsy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results